Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers ...
Zorevunersen is intended for treating Dravet syndrome. Credit: Maks_lab/Shutterstock. Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat ...
CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the ...
Through a new deal, Biogen has bought access to a potentially first-of-its-kind drug that some doctors and analysts see as a promising treatment for a rare form of epilepsy. Biogen on Tuesday ...
Piper Sandler analyst David Amsellem lowered the firm’s price target on Biogen (BIIB) to $135 from $138 and keeps a Neutral rating on the shares following quarterly results. Though Biogen has ...
Through a new deal, Biogen has bought access to a potentially first-of-its-kind drug that some doctors and analysts see as a promising treatment for a rare form of epilepsy. Biogen on Tuesday agreed ...
Biogen’s leadership has said they aren’t eager to deal, but turns out Stoke Therapeutics had a little something in its rare disease catalog that prompted Biogen to strike. The companies will work on a ...
Nguyen Thi Ngoc Diem, an Agent Orange victim in southern Vietnam.Credit...Linh Pham for The New York Times Supported by By Damien Cave Damien Cave reported from Dong Nai Province, where the U.S ...
Biogen's Q4 2024 earnings showed slight revenue ... The patent expiries of Tecfidera, Plegridy, and Tysabri have been chiefly responsible for the declines, and although Vumerity, approved in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results